Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1160908-11-1

C22H29N5O3 is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1160908-11-1 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1160908-11-1 Structure

  • Basic information

    1. Product Name: C22H29N5O3
    2. Synonyms:
    3. CAS NO:1160908-11-1
    4. Molecular Formula:
    5. Molecular Weight: 411.504
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1160908-11-1.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: C22H29N5O3(CAS DataBase Reference)
    10. NIST Chemistry Reference: C22H29N5O3(1160908-11-1)
    11. EPA Substance Registry System: C22H29N5O3(1160908-11-1)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1160908-11-1(Hazardous Substances Data)

1160908-11-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1160908-11-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,0,9,0 and 8 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1160908-11:
(9*1)+(8*1)+(7*6)+(6*0)+(5*9)+(4*0)+(3*8)+(2*1)+(1*1)=131
131 % 10 = 1
So 1160908-11-1 is a valid CAS Registry Number.

1160908-11-1Upstream product

1160908-11-1Downstream Products

1160908-11-1Relevant articles and documents

The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents

DeNinno, Michael P.,Andrews, Melissa,Bell, Andrew S.,Chen, Yue,Eller-Zarbo, Cynthia,Eshelby, Nan,Etienne, John B.,Moore, Dianna E.,Palmer, Michael J.,Visser, Michael S.,Yu, Li J.,Zavadoski, William J.,Michael Gibbs

, p. 2537 - 2541 (2009)

Starting from a non-selective pyrazolo-pyrimidone lead, the sequential use of parallel medicinal chemistry and directed synthesis led to the discovery of potent, highly selective, and orally bioavailable PDE9 inhibitors. The availability of these tools allowed for a thorough evaluation of the therapeutic potential of PDE9 inhibition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1160908-11-1